Status:
UNKNOWN
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Lead Sponsor:
Synta Pharmaceuticals Corp.
Conditions:
Solid Tumors
Eligibility:
All Genders
25+ years
Phase:
PHASE1
Brief Summary
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Detailed Description
This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.
Eligibility Criteria
Inclusion
- Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.
- Must have acceptable organ and marrow function per protocol parameters.
- No clinically significant ventricular arrythmias or ischemia.
Exclusion
- Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..
- No previous radiation to \>25% of total bone marrow.
- No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.
- No primary brain tumors or active brain metastases.
- No use of any investigational agents within 4 weeks.
- No treatment with chronic immunosuppressants.
- No uncontrolled, intercurrent illness.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2014
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00688116
Start Date
October 1 2007
End Date
November 1 2014
Last Update
September 18 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States
2
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
3
Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center
Boston, Massachusetts, United States, 02115
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115